title: True histiocytic lymphoma following B-acute lymphoblastic leukaemia: case report with evidence for a common clonal origin in both neoplasms.
abstract: True histiocytic lymphoma (THL) is a very rare type of non-Hodgkin's lymphoma (NHL) in which neoplastic cells exhibit markers of histiocytic differentiation. Some cases of THL have been reported in patients with previous acute lymphoblastic leukaemia (ALL), especially in children and young adults, in whom the acute leukaemia was of T-cell origin. The relationship between the initial lymphoid tumour and the secondary THL remains unclear, as a common monoclonal origin shared by both neoplasms has never been definitively demonstrated. We report a patient with B-ALL who developed a nodal and extranodal tumour with histological and immunohistochemical features of THL 4 years after the initial diagnosis. Genotypic study showed that both neoplasms contained the same immunoglobulin heavy gene rearrangement, which has not been reported previously.
authors.affiliation: Department of Haematology, Cancer Centre Institut Paoli-Calmettes, Université de la Méditerranée, Marseille, France. haemato1@marseille.fnclcc.fr
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: P
authors.initials: P
authors.lastname: Abéna
authors.forename: B
authors.initials: B
authors.lastname: Chetaille
authors.forename: T
authors.initials: T
authors.lastname: Aurran-Schleinitz
authors.forename: D
authors.initials: D
authors.lastname: Sainty
authors.forename: P
authors.initials: P
authors.lastname: Dubus
authors.forename: C
authors.initials: C
authors.lastname: Arnoulet
authors.forename: D
authors.initials: D
authors.lastname: Coso
authors.forename: L
authors.initials: L
authors.lastname: Xerri
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000150:complications* / Q000175:diagnosis / Q000235:genetics*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D015326:Gene Rearrangement, B-Lymphocyte, Heavy Chain; D006801:Humans; D007150:Immunohistochemistry; D017493:Leukocyte Common Antigens / Q000032:analysis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000175:diagnosis / Q000235:genetics*; D008297:Male; D016133:Polymerase Chain Reaction; D009418:S100 Proteins / Q000032:analysis; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D003520:Cyclophosphamide; D003606:Dacarbazine; D003630:Daunorubicin; D017493:Leukocyte Common Antigens; D009418:S100 Proteins; C067980:CD68 antigen, human; D000097382:CD68 Molecule